Back

Integrated Collagen Architecture and Composition Improve Risk Stratification in Triple-Negative Breast Cancer

Ozbilgic, R.; Dinc, B.; Vipparthi, K.; Seachrist, D.; Nicolas, M.; Keri, R. A.; Liu, X.; Yildirim, M.; Karaayvaz, M.

2026-05-14 cancer biology
10.64898/2026.05.11.724388 bioRxiv
Show abstract

PurposeTriple-negative breast cancer (TNBC) exhibits substantial clinical heterogeneity, with some patients experiencing early recurrence and poor survival despite similar clinicopathologic features. We sought to determine whether quantitative measures of intratumoral collagen architecture and composition derived from standard histopathologic specimens can identify patients at risk of recurrence and adverse survival outcomes. Experimental DesignWe analyzed a retrospective cohort of 79 TNBC tumors assembled into a tissue microarray using a multimodal computational pathology framework integrating Massons Trichrome staining with COL1 and COL3 immunohistochemistry. Collagen architecture was quantified using fiber-based image analysis and unsupervised clustering, while collagen composition was assessed using a normalized COL3:COL1 ratio. Associations with recurrence-free interval (RFI) and overall survival (OS) were evaluated using Kaplan-Meier analysis, restricted mean survival time (RMST), and Cox proportional hazards modeling. ResultsUnsupervised analysis identified four distinct collagen architectural states, which were consolidated into low-risk and high-risk groups based on recurrence patterns. High-risk collagen architecture was associated with significantly worse long-term RFI (log-rank p=0.025; RMST difference 10.1 months). Independently, a higher COL3:COL1 ratio was associated with improved OS (log-rank p=0.042; RMST difference 9.4 months). Integration of architectural and compositional biomarkers further refined risk stratification, identifying a subgroup with high-risk architecture and low COL3:COL1 ratio that exhibited the poorest survival outcomes. Notably, collagen-based stratification identified patients with divergent outcomes not readily predicted from tumor stage alone. ConclusionsQuantitative assessment of intratumoral collagen architecture and composition provides clinically meaningful prognostic information in TNBC and enables stratification of recurrence and survival risk. These findings support extracellular matrix phenotyping as a practical and scalable computational pathology approach for refining risk assessment in TNBC. Translational RelevanceTriple-negative breast cancer (TNBC) remains clinically challenging due to heterogeneous outcomes that are not fully captured by standard clinicopathologic variables. In this study, we demonstrate that quantitative features of intratumoral collagen architecture and composition, derived from routine pathology specimens, provide clinically meaningful prognostic information. Collagen-based biomarkers, including distinct collagen architectural phenotypes and the COL3:COL1 ratio, identify patient subgroups with distinct recurrence and survival outcomes, particularly among individuals whose risk is not adequately predicted by conventional staging. Importantly, these features can be extracted from widely available histological stains and immunohistochemistry, supporting the potential integration into existing pathology workflows. These findings support the tumor microenvironment as an underutilized source of biomarkers and suggest that extracellular matrix-based phenotyping may improve risk stratification and inform clinical decision-making in TNBC.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Breast Cancer Research
32 papers in training set
Top 0.1%
40.0%
2
npj Breast Cancer
18 papers in training set
Top 0.1%
6.9%
3
Scientific Reports
3102 papers in training set
Top 30%
4.0%
50% of probability mass above
4
The Journal of Pathology
22 papers in training set
Top 0.1%
3.7%
5
Cell Reports Medicine
140 papers in training set
Top 1%
3.6%
6
Cancers
200 papers in training set
Top 2%
3.6%
7
Clinical Cancer Research
58 papers in training set
Top 0.4%
3.6%
8
Nature Communications
4913 papers in training set
Top 44%
2.8%
9
International Journal of Cancer
42 papers in training set
Top 0.4%
2.8%
10
npj Precision Oncology
48 papers in training set
Top 0.3%
2.4%
11
Laboratory Investigation
13 papers in training set
Top 0.1%
2.1%
12
PLOS Computational Biology
1633 papers in training set
Top 17%
1.5%
13
Cancer Research
116 papers in training set
Top 3%
1.2%
14
PLOS ONE
4510 papers in training set
Top 59%
1.2%
15
Modern Pathology
21 papers in training set
Top 0.3%
1.1%
16
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.5%
1.1%
17
JNCI Cancer Spectrum
10 papers in training set
Top 0.5%
0.8%
18
JCI Insight
241 papers in training set
Top 6%
0.8%
19
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.8%
20
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
21
Journal of Translational Medicine
46 papers in training set
Top 3%
0.8%
22
Genome Medicine
154 papers in training set
Top 8%
0.7%
23
Nature Materials
21 papers in training set
Top 1%
0.7%
24
Annals of Biomedical Engineering
34 papers in training set
Top 1%
0.7%
25
eBioMedicine
130 papers in training set
Top 5%
0.7%
26
Molecular Cancer Research
42 papers in training set
Top 1%
0.5%
27
Cancer Research Communications
46 papers in training set
Top 2%
0.5%